100 doctors set up Immuno-Oncological Society to frame treatment norms

An innovation by IIT-Bombay may help reduce the cost of a type of immunotherapy used to treat blood cancer to a tenth of that in the US.

“We filed for a patent last month for the manufacture of the CAR-T cell therapy and hope it would eventually be available at a tenth of the US cost,” said Dr Rahul Purwar from IITB’s biosciences department. It would take another couple of years before the medicines are available for clinical trial at Tata Memorial Hospital, Parel.

100 doctors set up Immuno-Oncological Society to frame treatment norms

CAR-T cell therapy is one of the many immunotherapy agents that promise to treat cancer by tweaking a patient’s own immune system. While immunotherapy agents were used as the “last resort” for patients with advanced cancer till a few years back, it is emerging as the chosen treatment for certain cancers such as melanoma or that of the skin.

At a scientific meeting held at Tata Memorial on Saturday, around 100 doctors from across the country who are interested in immunotherapy, set up Immuno-Oncological Society of India. “This has been done to popularize and set up guidelines for this youngest branch of cancer treatment in India,” said medical oncologist Dr Jyoti Bajpai.

Earlier, cancer treatment was about surgery, chemotherapy and radiation. “But the nascent branch of immunotherapy is recording developments in cancer treatment on a monthly or weekly basis,” said her colleague Dr Gaurav Narula.

In the three years since Tata Memorial started a type of immunotherapy, 100 patients with advanced or metastatic form of the disease have been using it. “Around 30 patients are doing well,” said Dr Kumar Prabhash, adding it is too early to assess others on treatment.

The only hitch is the cost; the 100 patients at Tata Memorial pay from their pocket or insurance for the Rs 2-3 lakh a month treatment. One of their metastatic lung cancer patients has been on this treatment for 25 months and “feeling much better”, said Dr Prabash.

The IIT-B patent would cut the cost of only one type of immunotherapy that helps blood cancer patients. “We will tie up with a pharmaceutical company for manufacture and should be ready for clinical trial within a year or two,” said Purwar from IIT. The trial will be held at Tata Memorial. CAR-T cell therapy requires drawing blood from patients and separating out their T cells. A disarmed virus is then used to genetically change the T cells to produce chimeric antigen receptors or CARs. When injected, CARs targets blood cancer cells.

 Source:https://health.economictimes.indiatimes.com/news/medical-devices/100-doctors-set-up-immuno-oncological-society-to-frame-treatment-norms/63063628

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more